CDC to study infections linked to home infusion

The Centers for Disease Control and Prevention in Atlanta has launched a cooperative study with a medical corporation to investigate infections and other complications associated with home infusion therapy.

The primary purpose of the study is to determine the rate and risk factors for bloodstream infections in the home infusion therapy population. A secondary purpose is to gather data on the risk of blood contacts among home care workers providing home infusion therapy. The CDC will use the data to determine national baseline rates for bloodstream complications associated with home infusion therapy, and then may develop infection control guidelines.

"The data we will collect in the study is critically important because there are no current CDC guidelines in this area to help providers reduce the risk of bloodstream infections," says William Jarvis, MD chief of the investigation and prevention branch in the CDC hospital infections program.

The Coram Healthcare Corp. in Denver will participate in the study, which will run over an 18-month period at four of the company's patient care centers and two other unaffiliated centers. For its segment of the study, Coram will gather eight months of data, using random nurse participation among the 149 nurse employees in Coram's four study sites. Compilation of all study data and development of the final report to the CDC will be conducted by Mikalix and Co. based in Waltham, MA. *